JDP Therapeutics Inc., a privately held specialty pharmaceutical company, is pleased to announce that the Company has successfully completed the initial Phase 3 clinical trial (ETTAU-02) on its lead candidate JDP-205 in patients with acute urticaria associated with an acute allergic reaction. The result of this study has met and/or outperformed every parameter designed for this trial.
BLUE BELL, PENNSYLVANIA - The successful completion of the ETTAU-02 trial represents the achievement of a major milestone for the Company. JDP-205 has ...
Satisfied Users & 
Approved Press Releases
